Skip to main content

In-electrode faraday cage-type biosensors: Enclosing biorecognition for ultra-sensitive electrochemical and electrochemiluminescence detection

Journal
Biosensors & bioelectronics (Q1)
Published
10 September 2026
Study design
Narrative review / expert opinion
Evidence level
Level 5, Expert Opinion (CEBM 5)
Authors
Nastaran Arab, Andrea Salis, Morteza Hosseini, Guobao Xu, Lida Fotouhi
PMID
42732684
DOI
10.1016/j.bios.2026.119221

Why clinicians should know about it

  • Picked for Biochemistry (medical) (paper of the day, 16 September 2026): In‑electrode biosensor platforms, assay development relevance

Abstract

Electrochemiluminescence (ECL) and electrochemical biosensors traditionally rely on on-electrode, sandwich-type architectures in which only a small fraction of immobilized labels resides within the electrochemically active region, fundamentally limiting sensitivity. In recent years, a new class of Faraday-cage-type (FCT) or in-electrode biosensors has emerged as a powerful strategy to overcome these distance-dependent constraints. These systems employ conductive two-dimensional (2D) nanomaterials co-functionalized with biorecognition elements and signal labels that directly overlap the electrode surface, effectively extending the electroactive interface and relocating the outer Helmholtz plane to the surface of the 2D scaffold. As a result, all luminophores are positioned within the electron-transfer zone, enabling full utilization of labelling density and achieving substantial gains in ECL and electrochemical signal output. This review provides a comprehensive fabrication of FCT biosensors, covering their mechanistic foundations, structural components, and the diverse 2D nanomaterials used to construct high-performance signal units. We summarize recent advances in FCT-based detection of proteins, peptides, pathogens, and nucleic acids, highlighting how these architectures address long-standing limitations of conventional sandwich assays. Finally, we discuss current challenges and future opportunities for the development, standardization, and practical translation of FCT biosensing platforms. The rapid evolution of this field underscores the growing analytical potential of in-electrode architectures for ultrasensitive and clinically relevant biomarker detection.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.